Roche has revealed that a combination of Tecentriq and Cotellic tested in a late-stage trial failed to improve overall survival compared to regorafenib in patients with advanced metastatic colorectal cancer (CRC). The Phase III IMblaze370 […]
Janssen Pharmaceutica has announced results from two Phase III clinical studies of esketamine nasal spray, a drug closely related to ketamine, in patients with treatment-resistant depression. Presented at the American Psychiatric Association annual meeting, the […]
Merck has agreed to invest $125m in Moderna Therapeutics under a new agreement that expands the firms’ 2016 partnership to develop messenger RNA (mRNA) cancer vaccines. The deal now includes shared antigen mRNA cancer vaccines […]
Merck has entered into a development agreement with US-based SFJ Pharmaceuticals Group (SFJ) to develop abituzumab in metastatic colorectal cancer. Merck executive board member and Merck healthcare CEO Belén Garijo said: “Our collaboration with SFJ […]
Karyopharm Therapeutics’ selinexor, an oral selective inhibitor of nuclear export (SINE) compound, has succeeded in a phase 2b study by showing a 25.4% overall response rate (ORR) in heavily pretreated patients with refractory multiple myeloma. […]